AU6133394A - Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton - Google Patents

Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton

Info

Publication number
AU6133394A
AU6133394A AU61333/94A AU6133394A AU6133394A AU 6133394 A AU6133394 A AU 6133394A AU 61333/94 A AU61333/94 A AU 61333/94A AU 6133394 A AU6133394 A AU 6133394A AU 6133394 A AU6133394 A AU 6133394A
Authority
AU
Australia
Prior art keywords
targeting
genes
delivery
cells
antiviral agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61333/94A
Inventor
Glen R. Nemerow
Thomas J Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU6133394A publication Critical patent/AU6133394A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU61333/94A 1993-02-09 1994-02-03 Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton Abandoned AU6133394A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1522593A 1993-02-09 1993-02-09
US015225 1993-02-09
US4615993A 1993-04-13 1993-04-13
US046159 1993-04-13
PCT/US1994/001263 WO1994017832A1 (en) 1993-02-09 1994-02-03 Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton

Publications (1)

Publication Number Publication Date
AU6133394A true AU6133394A (en) 1994-08-29

Family

ID=26687112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61333/94A Abandoned AU6133394A (en) 1993-02-09 1994-02-03 Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton

Country Status (2)

Country Link
AU (1) AU6133394A (en)
WO (1) WO1994017832A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
WO1996029423A1 (en) * 1995-03-20 1996-09-26 Baylor College Of Medicine Compositions and methods for inducing infection by retroviral vectors outside of their host range
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
WO1997018317A1 (en) * 1995-11-13 1997-05-22 Commissariat A L'energie Atomique Dodecahedral adenoviral protein complex, composition containing same and uses thereof
FR2741087B1 (en) * 1995-11-13 1998-01-09 Commissariat Energie Atomique ADENOVIRAL DODECAEDRIC PROTEIN COMPLEX, PREPARATION METHOD, COMPOSITION CONTAINING THE SAME AND ITS APPLICATIONS
FR2747681B1 (en) * 1996-04-18 1998-06-19 Commissariat Energie Atomique ADENOVIRAL DODECAEDRIC PROTEIN COMPLEX, COMPOSITION CONTAINING THE SAME AND ITS APPLICATIONS
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
FR2761689B1 (en) 1997-04-02 1999-06-25 Transgene Sa MODIFIED ADENOVIRAL FIBER AND TARGET ADENOVIRUS
FR2761688A1 (en) * 1997-04-02 1998-10-09 Transgene Sa New adenovirus with mutations in the fibre protein to alter binding selectivity
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
FR2770537B1 (en) 1997-11-03 2001-06-01 Commissariat Energie Atomique PEPTIDE TRANSFECTION VECTOR, COMPOSITION CONTAINING IT AND THEIR APPLICATIONS
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1135688A2 (en) * 1998-12-04 2001-09-26 Novartis AG Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3)
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
IT1318704B1 (en) * 2000-09-22 2003-08-27 Consorzio Interuniversitario P CHEMICAL VECTORS AND THEIR USE FOR THE TRANSFER OF HETEROLOGICAL GENES.
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
AU2003271737B2 (en) 2002-04-25 2007-04-19 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
JP2007503843A (en) 2003-05-14 2007-03-01 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Increased adenovirus affinity
US8865182B2 (en) 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
CN108135966B (en) 2015-08-31 2021-12-28 基因药物株式会社 Composition for intracellular delivery comprising adenovirus protein VI-derived peptide and anticancer pharmaceutical composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells

Also Published As

Publication number Publication date
WO1994017832A1 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
AU6133394A (en) Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
AU4115693A (en) In vivo homologous sequence targeting in eukaryotic cells
AU1768192A (en) Rna delivery vector
AU5743996A (en) Compositions and methods for nucleic acid delivery to the lu ng
AU2095599A (en) Human genes and gene expression products i
AU9692198A (en) Gene delivery compositions and methods
AU5723696A (en) Gene therapy using replication competent targeted adenoviral vectors
AU3454093A (en) New lipophosphonic acid-nucleoside conjugates and their use as antiviral medicaments
AU7612196A (en) Functional human hematopoietic cells
AU7595498A (en) Medicament dispensing cell
AU4657593A (en) Personal cleanser with moisturizer
AU2946295A (en) Targeted gene delivery system
AU4182297A (en) Weight control pathway genes and uses therefor
AU2342900A (en) Novel interferon stimulated and repressed genes
AU4953793A (en) Multicistronic expression units and their use
GB9721909D0 (en) Gene delivery vectors and their uses
AU7272196A (en) Use of hyaluronan in gene therapy
AU6418498A (en) Human genes
AU3922593A (en) Genes and enzymes involved in the microbial degradation of pentachlorophenol
AU5457294A (en) Adenovirus-mediated ldl receptor gene transfer and targeting
AU4908197A (en) Gene expression and delivery systems and uses
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
GB9708526D0 (en) Eukaryotic gene expression cassette and uses thereof
AU6708994A (en) Foam cell drug delivery
AU1520499A (en) Essential fungal genes and their use